FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

	Check this box if no longer subject to
\neg	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Reasons Bryan M.				2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]								(Che	eck all applic	ionship of Reporting all applicable) Director		10% Ov	vner		
	,	ERAPEUTICS, I	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2021								Officer below)	(give title	Other (: below)		specify		
(Street) WAYNE (City)	PA	A	19087 (Zip)		4. If								Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Dat			2. Trans Date (Month/I	/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispos Code (Instr. 5)		Disposed	rities Acquired (A) ed Of (D) (Instr. 3, 4			5. Amour Securitie Beneficia Owned F Reported	s ally following	Form (D) or	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	,	Amount	(A) or (D)		Price	Transact (Instr. 3 a	ion(s)			(111511. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		Date, T	ransaction of code (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e C s F lly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				C	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or Nu of	umber					
Stock Option (Right to Buy)	\$21.9	06/03/2021			A		12,250		(1)(2)	00	5/02/2031	Commo Stock	n 12	2,250	\$0.00	12,250)	D	
Restricted Stock Units	(3)	06/03/2021			A		3,356		(1)(4)		(4)	Commo Stock	3	,356	\$0.00	3,356		D	

Explanation of Responses:

- 1. This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy.
- 2. The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date.
- $3. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ common \ stock \ of \ the \ issuer.$
- 4. The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date.

Remarks:

/s/ Mark Ballantyne, Attorney-

06/04/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.